LCDX Caliber Imaging & Diagnostics Reports Third Q
Post# of 94263
Posted On: 11/11/2013 8:11:56 AM
LCDX Caliber Imaging & Diagnostics Reports Third Quarter 2013 Results
Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., has released its financial results for the third quarter ended September 30, 2013. The Company has filed its Form 10-Q for the period ending September 30, 2013 which can be found on the Securities and Exchange Commission's website at www.sec.gov.
Business Highlights for the Third Quarter 2013:
• Announced two new distributors for its platform of VivaScope® confocal microscopes: Emdutos Industria e Comercio Ltda in the Brazilian market and Equipmed in the Australian and New Zealand markets.
• Introduced the VivaScope 1500 Multilaser System, which includes three lasers of different wavelengths that can be used in fluorescence-mode imaging to enhance image contrast when combined with dyes that are FDA-approved for human use.
• Significantly reduced costs as a result of product development programs initiated internally in 2012, including a redesign of optical and electrical components within the in-vivo confocal imagers to improve quality, manufacturability and functionality.
• Continued to receive positive client feedback about VivaScope systems from physicians and researchers at major hospitals and from pharmaceutical and cosmetic companies across the globe.
• Initiated recruitment efforts to bolster the executive management team as well as adding industry veterans to operations, sales and marketing.
• Acknowledged recent addition of confocal microscopy for the clinical management of basal cell carcinoma to the Guideline published by the European Dermatology Forum, reporting that confocal microscopy "has shown high diagnostic accuracy for the diagnosis of basal cell carcinoma."
Building Awareness & Engagement:
• Presented VivaScope imaging technology and corporate growth strategy at AdvaMed 2013: The MedTech Conference in Washington, DC (September).
• Described and demonstrated VivaScope devices at the Rodman & Renshaw Annual Global Investment Conference in New York City (September).
• Demonstrated VivaScope 3000 portable handheld confocal microscope system at the 1st Latin American Congress of Dermoscopy in Sao Paulo, Brazil (October).
• Exhibited VivaScope 1500 Multilaser and VivaScope 3000 portable handheld confocal microscope systems at the 64th American Association for Laboratory Animal Science National Meeting in Baltimore (October).
Media Placements:
• Boston Globe: Article titled "Laser imaging device makes no-cut biopsies possible" (October 14) focused on Caliber I.D.'s VivaScope devices. (Link here)
• Rochester Business Journal: Article titled "Caliber scopes out new focus" (October 18) reviewed Company's strategies for expanding its business. (Link here)
• Fox News: Video segment and article titled "New technology performs skin biopsies without the cutting" (October 29) noted benefits of noninvasive biopsy and profiled a New York City doctor who uses the system to diagnose lesions on his patients (Link here)
L. Michael Hone, Chief Executive Officer of Caliber I.D., said, "In the third quarter, we have continued to build the company by pursuing a variety of initiatives, led by the rollout of our VivaScope 1500 Multilaser System—the newest member of the VivaScope family. In addition, we have continued to benefit from the streamlining of operations in 2012, and by taking measures to enhance the management team. We continue to target a variety of facilities to convey the advantages of confocal microscopy as a tool for diagnosis in skin care. Based on the positive feedback we have been receiving from the medical community, at professional conferences, and as a result of media exposure, I am confident that we are on the right track and will witness improvement in the months and years ahead."
About Caliber Imaging & Diagnostics
Caliber Imaging & Diagnostics' platform of products offer increased productivity from the research laboratory to the doctor's office or the surgeon's operating room. Caliber I.D.'s platform of products provide precise accuracy, consistent reliability, and online backup that all combine to lead to better patient care. For more information about Caliber I.D. and its products, please visit www.caliberid.com.
VivaScope(R) is a registered trademark of Caliber Imaging & Diagnostics.
Safe Harbor
This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.
CONTACT: Richard Pulsifer
Chief Financial Officer
(617) 348-9821
Investor Relations:
Dian Griesel Int'l.
Cheryl Schneider
(212) 825-3210
cschneider@dgicomm.com
Public Relations:
Dian Griesel Int'l.
Susan Forman or Laura Radocaj
(212) 825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com
Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., has released its financial results for the third quarter ended September 30, 2013. The Company has filed its Form 10-Q for the period ending September 30, 2013 which can be found on the Securities and Exchange Commission's website at www.sec.gov.
Business Highlights for the Third Quarter 2013:
• Announced two new distributors for its platform of VivaScope® confocal microscopes: Emdutos Industria e Comercio Ltda in the Brazilian market and Equipmed in the Australian and New Zealand markets.
• Introduced the VivaScope 1500 Multilaser System, which includes three lasers of different wavelengths that can be used in fluorescence-mode imaging to enhance image contrast when combined with dyes that are FDA-approved for human use.
• Significantly reduced costs as a result of product development programs initiated internally in 2012, including a redesign of optical and electrical components within the in-vivo confocal imagers to improve quality, manufacturability and functionality.
• Continued to receive positive client feedback about VivaScope systems from physicians and researchers at major hospitals and from pharmaceutical and cosmetic companies across the globe.
• Initiated recruitment efforts to bolster the executive management team as well as adding industry veterans to operations, sales and marketing.
• Acknowledged recent addition of confocal microscopy for the clinical management of basal cell carcinoma to the Guideline published by the European Dermatology Forum, reporting that confocal microscopy "has shown high diagnostic accuracy for the diagnosis of basal cell carcinoma."
Building Awareness & Engagement:
• Presented VivaScope imaging technology and corporate growth strategy at AdvaMed 2013: The MedTech Conference in Washington, DC (September).
• Described and demonstrated VivaScope devices at the Rodman & Renshaw Annual Global Investment Conference in New York City (September).
• Demonstrated VivaScope 3000 portable handheld confocal microscope system at the 1st Latin American Congress of Dermoscopy in Sao Paulo, Brazil (October).
• Exhibited VivaScope 1500 Multilaser and VivaScope 3000 portable handheld confocal microscope systems at the 64th American Association for Laboratory Animal Science National Meeting in Baltimore (October).
Media Placements:
• Boston Globe: Article titled "Laser imaging device makes no-cut biopsies possible" (October 14) focused on Caliber I.D.'s VivaScope devices. (Link here)
• Rochester Business Journal: Article titled "Caliber scopes out new focus" (October 18) reviewed Company's strategies for expanding its business. (Link here)
• Fox News: Video segment and article titled "New technology performs skin biopsies without the cutting" (October 29) noted benefits of noninvasive biopsy and profiled a New York City doctor who uses the system to diagnose lesions on his patients (Link here)
L. Michael Hone, Chief Executive Officer of Caliber I.D., said, "In the third quarter, we have continued to build the company by pursuing a variety of initiatives, led by the rollout of our VivaScope 1500 Multilaser System—the newest member of the VivaScope family. In addition, we have continued to benefit from the streamlining of operations in 2012, and by taking measures to enhance the management team. We continue to target a variety of facilities to convey the advantages of confocal microscopy as a tool for diagnosis in skin care. Based on the positive feedback we have been receiving from the medical community, at professional conferences, and as a result of media exposure, I am confident that we are on the right track and will witness improvement in the months and years ahead."
About Caliber Imaging & Diagnostics
Caliber Imaging & Diagnostics' platform of products offer increased productivity from the research laboratory to the doctor's office or the surgeon's operating room. Caliber I.D.'s platform of products provide precise accuracy, consistent reliability, and online backup that all combine to lead to better patient care. For more information about Caliber I.D. and its products, please visit www.caliberid.com.
VivaScope(R) is a registered trademark of Caliber Imaging & Diagnostics.
Safe Harbor
This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.
CONTACT: Richard Pulsifer
Chief Financial Officer
(617) 348-9821
Investor Relations:
Dian Griesel Int'l.
Cheryl Schneider
(212) 825-3210
cschneider@dgicomm.com
Public Relations:
Dian Griesel Int'l.
Susan Forman or Laura Radocaj
(212) 825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com
(0)
(0)